You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
巴西卫生监管机构:中国批准紧急使用科兴生物新冠疫苗时的标准不透明
阿思达克 12-15 16:07
巴西卫生监管机构Anvisa表示,中国当局在批准紧急使用新冠疫苗方面做得不透明。此前巴西总统博索纳罗一直质疑科兴生物所研发的疫苗,认为疫苗的产地让人认为不值得被信任,但巴西圣保罗州长Joao Doria则称,预计1月开始为居民接种科兴生物疫苗。

不过在获得Anvisa批准之前,圣保罗将无法使用科兴生物的疫苗。Anvisa发声明称,该疫苗自今年6月开始在中国取得紧急使用授权,但认为中国批准紧急使用授权时的标准不透明,亦无法获知中国当局作出相关决定时所依据的资料。

目前该疫苗正在圣保罗进行第三阶段测试,Doria周一曾表示,疫苗成效率将於12月23日发布,比原先计划迟了9日,但届时会提供更多样本及更完整的分析。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account